Theradiag SA develops, manufactures, and markets in-vitro diagnostic products. It offers autoimmunity reagents; IMMUNO-TROL, a multi-parametric quality control tool; various instruments for autoimmunity and infectious diseases testing; SQA-V system, a semen analyzer; and V-Sperm for loading results, pictures, and videos of the samples into the computer. The company also provides instrumentation, including Theralis that integrates multiplex FIDIS immunofluorescence and ELISA; Theralis µ, a solution for medium sized laboratories; and FIDIS platform used in laboratory for analysis. In addition, it offers therapeutic drug monitoring services for treatment of chronic inflammatory diseases; and LISA tracker, a tool for monitoring of biotherapies, as well as Elisa and rapid tests for SARS-CoV 2 serology. The company was founded in 1986 and is based in Marne La Vallee, France.

EURONEXT:ALTER

Theradiag SA

Last Close

1.32

15/12 16:08

Market Cap

17.29M

Beta: −0.26

Volume Today

31.61K

Avg: 3K

PE Ratio

−33.61

PFCF: −10.36